Serum Vitamin D Levels as a Prognostic Biomarker in Patients Receiving Immune Checkpoint Inhibitors
Journal of Oncological Science, cilt.12, sa.1, ss.1-8, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 12 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.37047/jos.galenos.2025.2025-11-2
- Dergi Adı: Journal of Oncological Science
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.1-8
- Anahtar Kelimeler: immune checkpoint inhibitors, prognostic biomarkers, survival, Vitamin D
- Hacettepe Üniversitesi Adresli: Evet
Özet
Objective: Vitamin D exerts pleiotropic effects on tumor biology and immune regulation, including modulation of T-cell function and antigen presentation. Preclinical evidence suggests that optimal vitamin D status may enhance immune checkpoint inhibitor (ICI) efficacy; however, data are limited among ICI-treated patients. We aimed to evaluate the prognostic significance of baseline serum 25(OH)D levels in patients receiving ICIs. Material and Methods: A retrospective cohort of 244 patients with advanced solid tumors treated with ICI. Baseline serum 25(OH)D concentrations, obtained within 30 days prior to ICI initiation, were categorized as sufficient (>20 ng/mL), insufficient (12-20 ng/mL), or deficient (<12 ng/mL). Results: The median age of the patients was 63 years; 65.2% were male. The most common tumor types were non-small cell lung cancer (32.8%), renal cell carcinoma (18.9%), and melanoma (14.3%). Vitamin D status was sufficient in 36.5%, insufficient in 34.8%, and deficient in 28.7% of patients. In multivariable analysis, vitamin D deficiency independently predicted shorter overall survival (OS) [hazard ratio (HR): 2.264, 95% confidence interval (CI): 1.553-3.300; p<0.001] compared with the vitamin D-sufficient group. Both vitamin D insufficiency (HR: 1.494; 95% CI: 1.067-2.092; p=0.019) and vitamin D deficiency (HR: 2.0; 95% CI: 1.411-2.833; p<0.001) were independently associated with inferior progression-free survival (PFS). Conclusion: Baseline vitamin D deficiency is an independent adverse prognostic factor for OS and PFS in ICI-treated patients. Integrating vitamin D assessment into pretreatment evaluation may facilitate risk stratification and inform supportive care strategies, warranting prospective validation.